Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C24H24FN3O2.ClH |
| Molecular Weight | 441.926 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.FC1=CC=C(C=C1)C2=CN=CC(CN3CCN(CC3)C4=CC=CC5=C4OCCO5)=C2
InChI
InChIKey=PAPGPUNOWOEIPA-UHFFFAOYSA-N
InChI=1S/C24H24FN3O2.ClH/c25-21-6-4-19(5-7-21)20-14-18(15-26-16-20)17-27-8-10-28(11-9-27)22-2-1-3-23-24(22)30-13-12-29-23;/h1-7,14-16H,8-13,17H2;1H
DescriptionCurator's Comment: description was created based on several sources, including
http://www.solvay.com/en/binaries/20080930_Pharma-135290.pdf
Curator's Comment: description was created based on several sources, including
http://www.solvay.com/en/binaries/20080930_Pharma-135290.pdf
Adoprazine (SVL-313) is a full 5-HT1A receptor agonist and full D2/3 receptor antagonist possessing characteristics of an atypical antipsychotic, representing a potential novel treatment for schizophrenia and bipolar disorder. This drug together with some others, e.g. Mazapertine succinate, PF-217830 was discontinued from clinical trials due to either non-optimal pharmacokinetic properties or insufficient therapeutical efficacy.
Originator
Approval Year
Overview
| CYP3A4 | CYP2C9 | CYP2D6 | hERG |
|---|---|---|---|
OverviewOther
| Other Inhibitor | Other Substrate | Other Inducer |
|---|---|---|
Drug as perpetrator​
| Target | Modality | Activity | Metabolite | Clinical evidence |
|---|---|---|---|---|
| yes [IC50 10.684 uM] | ||||
| yes [IC50 4.7724 uM] | ||||
| yes [IC50 9.5221 uM] |
Drug as victim
| Target | Modality | Activity | Metabolite | Clinical evidence |
|---|---|---|---|---|
| no |
Sample Use Guides
In Vitro Use Guide
Curator's Comment: SLV313 (ADOPRAZINE) possessed high affinity at human recombinant D(2), D(3), D(4), 5-HT(2B), and 5-HT(1A) receptors, moderate affinity at 5-HT(7) and weak affinity at 5-HT(2A) receptors, with little-no affinity at 5-HT(4), 5-HT(6), alpha(1), and alpha(2) (rat), H(1) (guinea pig), M(1), M(4), 5-HT(3) receptors, and the 5-HT transporter. SLV313 had full agonist activity at cloned h5-HT(1A) receptors (pEC(50)=9.0) and full antagonist activity at hD(2) (pA(2)=9.3) and hD(3) (pA(2)=8.9) receptors.
Unknown
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
42631781
Created by
admin on Sat Dec 16 08:12:32 GMT 2023 , Edited by admin on Sat Dec 16 08:12:32 GMT 2023
|
PRIMARY | |||
|
222551-05-5
Created by
admin on Sat Dec 16 08:12:32 GMT 2023 , Edited by admin on Sat Dec 16 08:12:32 GMT 2023
|
PRIMARY | |||
|
R8E4GUG6DQ
Created by
admin on Sat Dec 16 08:12:32 GMT 2023 , Edited by admin on Sat Dec 16 08:12:32 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD
